

1 Disease Triangle Dynamics of Coccidioidomycosis in Northern Arizona

2

3 **Article Summary Line:** Our work is the first description of the Valley fever disease triangle in
4 Northern Arizona, which considers the complex interaction between host, pathogen and
5 environment in the region. Our data suggests that the prevalence of diagnosed cases is rising in
6 the region, some of which are extreme enough to necessitate hospitalization. We present the first
7 evidence of *Coccidioides* spp. in Northern Arizona soils, suggesting that the pathogen is
8 maintained in the local environment. Until disease prevention is an achievable option via
9 vaccination, we anticipate that incidence of Valley fever will rise in the area. Therefore,
10 enhanced disease awareness and screening for the coccidioidomycosis is vital to the communities
11 of Northern Arizona.

12

13 Heather L. Mead^{1,2}, Dan Kollath¹, Marcus de Melo Teixeira³, Chandler C. Roe¹, Paul K. Keim¹,
14 Carmel Plude^{2,4}, Joel Terriquez⁴, Nivedita Nandurkar⁴, Chelsea Donohoo⁵, Brettania L.W.
15 O'Connor⁶, Bridget M. Barker^{1*}

16

17 ¹Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ. 86011. U.S.A

18 ²Translational Genomics Research Institute (TGen), Phoenix and Flagstaff, AZ. USA

19 ³Faculty of Medicine, University of Brasilia, Brasilia. Brazil

20 ⁴ Northern Arizona Healthcare, Flagstaff, AZ. 86001. U.S.A.

21 ⁵ Coconino County Health Department, Flagstaff, AZ. 86004. U.S.A.

22 ⁶Department of Health Sciences Northern Arizona University, Flagstaff, AZ. 86011. U.S.A.

23 *Corresponding author

24 **Abstract**

25 *Coccidioides* species are the etiological agent of Valley fever (Vf). Disease ranges from
26 pneumonia to extrapulmonary infection. If diagnosis is delayed or missed, the risk of severe
27 disease increases. We investigate the disease triangle (intersection of pathogen, host, and
28 environment) of Vf in Northern Arizona, where the risk of acquiring the disease is lower but
29 prevalent and rising. We inspect reported and hospitalized cases of VF hosts. Then assess
30 pathogen origin by comparing Northern Arizona clinical isolates to isolates from other regions.
31 Lastly, we survey Northern Arizona soils for evidence of *Coccidioides*. We found that cases of
32 Vf are increasing some requiring hospitalization. The Northern Arizona *Coccidioides* isolates
33 were genetically related to Southern Arizona populations. However, we detected *Coccidioides*
34 DNA in Northern Arizona soils. We expect that cases will continue to increase and suggest
35 increased awareness and screening for the disease is crucial to limit severe illness in Northern
36 Arizona.

37 **Keywords:** coccidioidomycosis, Valley fever, disease triangle, fungal infection, diseases of
38 southwestern united states, endemic fungi, Northern Arizona

39 **Introduction**

40 The disease triangle is a concept which includes the interaction between host, pathogen and the
41 environment. Infectious diseases can emerge when a vulnerable host, virulent pathogen and
42 favorable environmental conditions complete the triangle (1). This framework has been applied
43 to a wide variety of diseases that affect both plants and animals (2, 3). Lessons can be learned
44 from the famous potato famine in Ireland and applied to protect future crop security (1).
45 Similarly, during the global COVID-19 pandemic these interactions are under scrutiny to
46 determine and monitor the animal reservoir of the novel SARS-CoV-2 virus (4-6). Clearly, the

47 disease triangle is a critical perspective for considering infectious diseases and predicting future
48 implications for human health. One environmentally acquired fungal infection of concern is
49 coccidioidomycosis (Valley fever), caused by two *Coccidioides* species. Alarming, cases of
50 this disease are increasing nationwide (7-9).

51 Valley fever in humans can be self-limited, requiring little to no medical care, or chronic
52 causing years of treatment and/or life-long symptoms (10). Infection occurs when aerosolized
53 environmental arthroconidia are inhaled by a susceptible host, thus, Valley fever typically
54 manifests as a respiratory infection which presents as asymptomatic, acute or fibrocavitary
55 chronic pneumonia (11). In severe cases, dissemination to extrapulmonary sites, such as the
56 skeletal or the central nervous system occurs and requires life-long antifungal treatment (10, 11).
57 This broad range of clinical symptoms makes determining yearly case burden challenging, but
58 estimates range from 150,000 - 350,000 cases/year in the United States (8, 12). Fortunately, for
59 many patients the disease can be asymptomatic or present as self-limited pneumonia not
60 requiring clinical intervention. Unfortunately, for symptomatic patients, misdiagnosis occurs
61 frequently, which contributes to the inappropriate use of antibiotics or long delays in correct
62 treatment (9, 13). Therefore, reported cases underestimate actual cases due to individuals not
63 seeking medical care, misdiagnosis and underreporting (8, 14). In known endemic regions,
64 approximately 30% of community acquired pneumonia cases are known to be due to Valley
65 fever, but patients are infrequently tested for Valley fever and thus not reported (15-17).
66 Preventing infection is difficult because even at individual locations the occurrence of detectable
67 airborne fungal particles can fluctuate daily, consequently any public health warnings based on
68 detection would be delayed (18, 19). The underlying mechanisms which contribute to host
69 susceptibility are elusive, preventing the identification of all highly susceptible individuals as a

70 prevention strategy (20). Lastly, despite decades of research, a viable vaccine has not been
71 identified (21, 22). Therefore, an important part of combating this disease currently requires
72 defining the patterns of host susceptibility, pathogen virulence potential and environmental
73 requirements which support the lifecycle. Which approach contributes towards improved
74 awareness among community members, healthcare professionals and infectious disease
75 researchers.

76 Retrospective studies based on medical records are typically used to identify host specific
77 factors which contribute to the Valley fever disease triangle (16, 17, 23-26). This approach is
78 helpful but incomplete as asymptomatic or mild cases that did not require a medical visit are not
79 included. Nevertheless, these strategies have identified several factors which increase host
80 disease susceptibility. Substantial evidence shows there are differences in risk of Valley fever
81 disease severity by race. Individuals of African or Filipino descent are a recognized risk group
82 for severe disease, in particular disseminated infection (26). Recently, Native American
83 populations have been suggested to have increased dissemination and hospitalization rates (27).
84 The underlying mechanisms responsible for increased disease vulnerability are undefined (28).
85 These observations are complicated by the uneven distribution of races in endemic areas, uneven
86 sample sizes and the potential effect of socioeconomic and other underlying factors. These
87 complications do not nullify the indication of increased risk among specific populations, but
88 rather validate the need for in-depth studies which consider these aspects (29). Lastly, while
89 many fungal diseases are restricted to immunocompromised individuals, coccidioidomycosis
90 occurs in seemingly healthy individuals as well which could be due to undescribed host factors
91 (30-32). In general, many host specific aspects which dictate Valley fever disease outcomes are
92 undefined or incomplete, which prevents identifying all high-risk populations(9, 25).

93 The evolution of a host-specific lifecycle, which is distinct from the environmental
94 lifecycle, contributes to *Coccidioides*' virulence potential causing disease in humans and other
95 mammals (33). When the environmental fungal arthroconidia (asexual spore structure) are
96 inhaled by a mammal, they swell into large structures called spherules which are uniquely
97 adapted for survival and proliferation in the host (34, 35). These fungi have developed
98 thermotolerant strategies to survive at high temperatures, such as those encountered in the human
99 body, subsequently increasing pathogenic potential (36). In addition, genomic analyses suggest
100 that in comparison to common ancestors *Coccidioides* experienced a reduction in genes needed
101 to degrade plant material, a common nutrition source for many fungi, and gained the ability to
102 degrade a variety of animal proteins (37). Molecular systematics and taxonomical studies have
103 determined that the *Coccidioides* genus is comprised of two species, *C. immitis* and *C. posadasii*
104 (38, 39). Both of these species create the host specific endospore structure, that is
105 not observed in other dimorphic fungi (33). Each species has defined subpopulations with
106 substantial genetic variation (40-42). Currently, it is unknown if virulence or the ability to cause
107 disease varies among strains beyond what has been observed in mice or in dated literature (30,
108 43-46). So far, no specific allelic distributions of fungal virulence phenotypes are associated with
109 specific disease symptoms. This is in part because little work has been conducted in this area,
110 though variation in virulence among isolates of *Coccidioides* has been suggested (43, 45, 47).
111 This missing and crucial information specific to virulence potential could explain the observed
112 disparity in disease manifestation among individuals and should be investigated.

113 The environmental niche which supports existence of *Coccidioides* has not been
114 completely defined but it is hypothesized that the fungi co-evolved with desert mammals, such as
115 rodents (48, 49). Thus, the pathogen can frequently be detected in the tissue of wild mammals,

116 burrows, or archeological sites that are likely enriched with animal-derived organic matter (39,
117 50-53). In these situations, it is suggested that the fungi exist as mammalian endozoans which
118 survive within the host without causing symptoms and benefit by having direct access to
119 nutrition upon host demise (48). The known environmental distribution of the pathogen includes
120 arid zones of Latin America, ranging from Mexico to Argentina and the southwestern United
121 States (40, 54). Recently, the recognized range of the pathogen expanded with locally acquired
122 cases occurring in northwestern states, such as Washington (55, 56). Alarming, the
123 environmental distribution of *Coccidioides* is predicted to continue to expand in response to
124 climate variability (57, 58). Regions of the southwest that were not traditionally considered
125 endemic will likely serve as suitable habitat for the pathogen in the near future and subsequently
126 it is expected that cases of Valley fever will continue to rise (59).

127 Historically, Arizona has reported the highest number of diagnosed cases of Valley fever
128 nationwide each year, except in 2018 when Arizona was surpassed by California (7, 9). In
129 moderately or suspected endemic regions such as Northern Arizona, the risk of acquiring disease
130 is lower than in established endemic regions, but still prevalent (60). Subsequently, infection is
131 often attributed to travel or prior residence in highly endemic regions. Because the risk of Valley
132 fever is lower across Northern Arizona compared to highly endemic counties of southern
133 Arizona there is potential that diagnosis can be delayed or missed due to lack of awareness and
134 testing (61). Northern Arizona encompasses a third of the state and is divided into five counties,
135 Mohave, Yavapai, Coconino, Apache and Navajo (Figure 1). As with the rest of the state, the
136 incidence of new cases in Northern Arizona is on the rise (62, 63). However, data on
137 patients/cases from the region is often grouped with the rest of the state, with most discussion
138 focused on the southern counties Maricopa, Pima and Pinal, with the highest proportion of

139 reported cases. The environmental factors and potential host population demographics in
140 Northern Arizona are very different from counties to the south. The region is predicted to further
141 support the pathogen's survival in the near future, but little focus has been placed on the current
142 disease burden of the region (58).

143 Herein, we conduct the first focused investigation of coccidioidomycosis in humans in
144 Northern Arizona. We investigate susceptible populations, origins of infection and the potential
145 for the environment to support the pathogen. Our goal is to document the region-specific
146 implications for human health in regard to Valley fever, providing a reference for future
147 investigations and public health awareness campaigns.

148 **Methods**

149 This project utilized four data sources. 1) Public health records to capture reported Valley fever
150 in Northern Arizona counties between year-year. 2) Hospital chart data to capture in patient
151 Valley fever trends at Northern Arizona Healthcare 3) Genomic DNA from clinical isolates
152 obtained at the Northern Arizona Healthcare. 4) DNA extracted from soil in Northern Arizona
153 counties.

154 1) Public Health records: Yearly, county case reports (2017, 2018 and 2019) and historical
155 averages (2012-2016) per 100,000 population were accessed through the Arizona Department of
156 Health Services (AZDHS) website.

157 2) Hospital Records: A retrospective chart review was performed to identify all in-patients that
158 were screened for Valley fever during an 18-month period (7/1/17-12/31/18) at the Flagstaff
159 location of Northern Arizona Healthcare. Screening was defined as when a patient was subjected
160 to Valley fever evaluations through x-ray, titer or complement fixation serological diagnostics.
161 Confirmed positive diagnoses were defined as; positive IgM, titer >1.8. These confirmed positive

162 cases were reviewed by the infectious disease department to definitively confirm diagnosis.

163 Individual medical records with confirmed coccidioidomycosis cases were further investigated

164 for demographic and comorbidity information.

165 3) Fungal Isolates: The fungal clinical isolates were previously collected and stored under IRB

166 No. 764034 as part of the Northern Arizona University Biobank study with Northern Arizona

167 Healthcare. For this study, these isolates (Supplemental Table 1) were transferred to the

168 Pathogen and Microbiome Institute biosafety level three (BSL-3) facility. Personal protective

169 equipment and pathogen manipulation occurred as previously described recommended by the

170 Biosafety in Microbiology or Biomedical Laboratories (64, 65).

171 Fungal Growth, Nucleic Acid Extraction and Sequencing: Fungal isolates were cultured as

172 previously described (65, 66). Briefly, to confirm pure cultures the isolates were grown on

173 2xGYE (2% glucose, 1% yeast extract agar) at 30°C, for seven days. Next, small plugs of each

174 isolates were used to inoculate liquid 2xGYE (2% glucose, 1% yeast extract) in vented baffled

175 Erlenmeyer flasks and grown at 30°C, for six days on a shaking incubator. These cultures were

176 heat inactivated at 80°C for 30 min in fungal lysis buffer. Genomic DNA was obtain used

177 traditional phenol:chloroform solvents and precipitated using isopropanol and EtOH. DNA

178 quantity and quality was visualized on a 1% agarose gel. These samples were submitted for

179 sequencing at the Translation Genomics Research Institute on a MiSeq V3 kit for 600 cycles.

180 Raw reads have been deposited under accession number PRJNA722304.

181 Population *Analysis*: Raw reads for 60 previously published *C. posadasii* samples representing

182 the Caribbean, Arizona, Texas/Mexico/South America clades (40) and the seven new clinical

183 isolates were aligned to reference *C. posadasii* stain Silveira genome, accession number

184 JADMCF000000000. Using the Northern Arizona Sequencing Pipeline (67) in order to retrieve

185 DNA mutations. The resulting SNP (Single Nucleotide Polymorphism) matrix was used to build
186 a Maximum Likelihood tree using IQ-TREE version 1.6.1, based in 152,663 parsimony
187 informative SNP's (68). The phylogenetic tree distribution was visualized using Figtree v1.4.4
188 (69).

189 4) Soil Collection, Nucleic Acid Extraction and Amplification: A total of 171 soil samples
190 collected between 2018-2020 were included in this study (see Supplemental Table 2 for
191 breakdown of samples and site descriptions). The sites in Northern Arizona drastically vary in
192 ecosystem characteristics from each other as well as from habitat in the highly endemic Southern
193 Arizona region for Valley Fever. Soils were collected and processed as previously described
194 (49). Briefly, each sample was collected with a sterile garden trowel and stored in sterile 50 mL
195 collection containers at room temperature until processing. DNA was extracted following kit
196 recommendations using the Qiagen DNeasy Powersoil Pro Kit (Qiagen, Boston, MA, USA). The
197 presence or absence of *Coccidioides* spp. DNA in soil samples was determined by two highly
198 specific Taqman-based CoccoiCDX and CoccoiENV real-time qPCR assays using a Quant Studio
199 12k Flex Real-Time PCR System (ThermoFisher Scientific (70, 71). Each 20uL reaction
200 contained 1 x Taqman Universal Master mix II (ThermoFisher Scientific), PRIMERS, with DNA
201 template with the following thermocycling conditions: initial denaturation for 10 min at 95°C
202 followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Three technical replicates were run for
203 each DNA sample. A reaction was considered positive if it showed logarithmic amplification,
204 produced a CT value of <40.


205 **Results**

206 We sought to identify the number of recent diagnosed cases (2017-2019) of coccidioidomycosis
207 in Northern Arizona compared to historical averages (2012-2016) and to compare the host

208 specific factors of these cases to statewide trends. After which we focused on the in-patient
209 Valley fever patient population of Northern Arizona by performing a chart review during a
210 similar (18 month) time frame at the regional hospital. We then investigated the genetic structure
211 of fungal isolates collected and stored at the hospital compared to the recognized populations of
212 *Coccidioides*. Lastly, we searched for evidence of pathogen presence in Northern Arizona soils,
213 completing our epidemiologic triangle approach.

214 *Diagnosed Valley fever cases are increasing in Northern Arizona counties*

215 Northern Arizona counties are experiencing increased cases of Valley fever per 100,000
216 population compared to the historical trends defined by the health department (Figure 1). We
217 focused on 2017-18 as this time frame coincides with the hospital data available to us and chose
218 to also include 2019 data. In Mohave, Yavapai and Apache counties the number of cases per
219 100,000 population doubled by 2019 in comparison to historical averages (Figure 1,
220 supplemental table 3). These findings are similar in counties across the state. The greatest
221 number of cases reported each year occur in Maricopa, Pima and Pinal counties which are
222 located in Southern Arizona (Figure 1). In general, all of the counties in Arizona are reporting an
223 increase in diagnosed cases each year and an increase in incidence per 100,000 population
224 (supplemental table 3 and 4) with a few exceptions. The age and sex of individuals testing
225 positive for Valley fever in northern counties are similar to statewide observations (supplemental
226 table 5).



227

228

229 Figure 1. Northern Arizona county location and Valley fever cases. Yearly, the number of cases
 230 per 100,000 population are increasing compared to historical averages in all Northern Arizona
 231 counties. Geographic location of northern Arizona counties. Left to right, Mohave, Yavapai,
 232 Coconino (largest), Navajo and Apache. Tribal land located in Northern Arizona counties are
 233 shaded. The southern counties which experience the highest yearly case counts per 100,000 are
 234 denoted with asterisks.

235


236 *Valley fever hospitalizations in Coconino county*

237 Next, we surveyed all in-patient records at the regional hospital, Northern Arizona Healthcare
 238 (NAH) for an 18-month period (7/13/2017-12/31/2018). The relatively short timeframe of this
 239 retrospective review is a limitation of this study. Therefore, the previously mentioned county
 240 case data was identified to complement the timeframe of this chart review. This regional medical
 241 center is located in Coconino county and often accepts patients from other Northern Arizona

242 counties. During the time frame we investigated, there were 124 in-patients screened for Valley
243 fever, 38 of them were positive for coccidioidomycosis (IgM 28, titer 16). Because statewide
244 coccidioidomycosis hospitalization demographic data is not publicly available we compared
245 these in-patient cases to all reported coccidioidomycosis case in Arizona in respect to sex and
246 age (supplemental table 5, Figure 2A). In Arizona, reported cases of Valley fever is distributed
247 approximately 50/50 among males and females with slight fluctuation each year (60). Of the 38
248 hospitalized patients there were 23 males (60.5%) and 15 females (39.5%). The greatest
249 proportion of Arizona confirmed cases and in-patient cases occurred among individuals between
250 45-64 years of age. Among all 38 Valley fever hospital patients, we observed a range of
251 comorbidities; diabetes (16%), cancer (10%), HIV (5%) or in some cases multiple conditions
252 (25%). In total 23% of hospitalized patients did not have notable co-morbidities and were
253 otherwise healthy (Figure 2B). For the 38 hospitalized cases, 82% of the fungal infections were
254 restricted to pulmonary locations, and 18% experienced dissemination to other regions of the
255 body (Figure 2C). Nationally, dissemination only occurs in between 1-5% of reported Valley
256 fever cases (25).

257 Next, we sought to compare racial demographics in NAH Valley fever cases with
258 Arizona trends. Published literature suggests that individuals with African American or Filipino
259 backgrounds are at increased risk for severe Valley fever (26, 72). Shockingly, in Arizona
260 race/ethnicity is documented for only ~29% of diagnosed cases (Table 1). This makes assessing
261 especially vulnerable populations based on racial variation challenging and potentially
262 inaccurate. At NAH, we were able to identify race/ethnicity in all cases (Table 1, Figure 2C).
263 There were 14 white (36.8%), 2 Hispanic (5.2%) and 22 Native American/Alaskan Indian
264 (57.8%) cases. The observed proportion of diagnosed cases among individuals with Native

265 American/Alaskan Indian heritage appears high (57.8%) despite the population prevalence
 266 (25.9%) in Coconino county and at NAH (35%) compared to other ethnic groups (Table 1). This
 267 trend may be similar to findings released by the CDC which documented increased
 268 hospitalization in native American populations with Valley fever. However, statewide examining
 269 data when race is known, only 2.1% of the cases are observed in Native American/Alaskan
 270 Indian individuals, who make up 4.1% of the state's total population (Table 1).



271
 272 Figure 2. Northern Arizona Valley fever data demographics. 2A) Age of patients diagnosed with
 273 Valley fever in Arizona during 2018, Northern Arizona counties during 2018, and regional
 274 hospital (NAH) between (7/13/2017-12/31/2018). 2B) Among hospitalized Valley fever patients
 275 at NAH 23% of patients had no documented pre-existing conditions. The other 77% had existing
 276 co- morbidities such as diabetes (16%), HIV (9%), cancer (10%), and is several cases multiple
 277 immunocompromising conditions. 2C) The total population treated at NAH is displayed next to
 278 in-patient Valley fever cases for reference. Out of the 38 patients diagnosed with Valley fever

279 from (7/13/2017-12/31/2018) pulmonary infection occurred in 31 (82%) cases, dissemination to
 280 extrapulmonary locations occurred in 7 (12%) of the cases. There were 14 white (36.8%), 2
 281 Hispanic (5.2%) and 22 Native American/Alaskan Indian (57.8%) individuals.

282 Table 1. Breakdown of unknown and known race distribution for Valley fever cases in Arizona,
 283 Coconino county and Northern Arizona Health Care.

Total population and Valley fever cases for state, county, and hospital demographics						
Group	Arizona % (n)		Coconino county % (n)		Northern Arizona Healthcare % (n)	
	Population*	Valley fever**	Population*	Valley fever**	Population***	Valley fever
Unknown	n/a	72.1% (5,388)	n/a	22	1.5 % (399)	0
All groups	7,278,717	7,478	143,476	46	27,008	38
White non-Hispanic	55.38% (3,981,049)	17.6% (1,317)	63.9 % (91,649)	14	52.2 % (14,096)	36.84 % (14)
Hispanic or Latino	31.7% 2,279,253	4.3% (325)	14.27 % (21,023)		8.3 % (2,255)	5.26 % (2)
Black or African American	4.898% 352,121	2.1% (159)	1.0 % (1,364)		1.2 % (324)	0
American Indian or	4.161% 299,123	2.1% (157)	25.9 % (37,187)	10	35.3 % (9,531)	57.89 % (22)

Alaska Native						
Asian or Pacific Islander	3.86% 277,474	1.1% (84)	2.2 % (3,149)		0.8 % (225)	0
Other/Two or more	3.9% 280,574	0.6% (48)	4.3% (6,230)		0.7% (178)	0

284


285 *ACS 2019 estimates census.gov

286 ** Arizona Department of Health 2018 annual Valley fever report. Only 29% of cases' ethnicity
287 is known so data is unreliable.

288 *** Northern Arizona Healthcare, Flagstaff location 2017, 2018

289 *Northern Arizona Clinical isolates originate from Arizona Coccidioides populations*


290 We obtained seven *Coccidioides* isolates from the Northern Arizona Healthcare patient
291 population. We used 60 previously published whole genome paired end reads and recently
292 release PacBIO assembly, *C. posadasii* strain Silveira reference to build a SNP (single nucleotide
293 polymorphism) based matrix. A total of 82.72% or 23,336,819 bases mapped to the reference
294 genome from which we detected 270,853 SNP's. Next, the IQTREE software was used to
295 identify the best nucleotide substitution model, TVM+F+ASC+R5 using 1,000 bootstrap
296 iterations to the distinguish the Maximum Likelihood tree. This analysis demonstrated that the
297 isolates obtained from patients at Northern Arizona Healthcare are genetically similar to either
298 isolates from Maricopa (n=4) or Pima (n=3 counties) and no unique genetic clusters were found
299 for the Northern Arizona samples.



300
 301 Figure 3. Relationship of Northern Arizona Clinical isolates within *C. posadasii* population
 302 suggests traveled related infection. The seven new clinical isolates (highlighted) group with
 303 previously published isolates recovered from patients in Maricopa or Pima county populations.
 304 *C. posadasii* is comprised of geographically distinct populations designated as Caribbean (top,
 305 red), Texas/Mexico and South America (bottom, yellow) and Arizona (middle, blues).
 306 Subpopulation structure in Arizona suggests genetically distinct groups with Arizona (Maricopa
 307 county; Phoenix and Pima county; Tucson). Mid-point Rooted Maximum Likelihood Tree built
 308 using 61 previously published and seven new isolates.
 309 *Coccidioides spp. are present in Northern Arizona soil samples.*

310 We surveyed 171 soil samples obtained between 2018-2020 from Mohave, Yavapai,
311 Coconino, Navajo and Apache county for the evidence of *Coccidioides* DNA. We identified
312 positive samples in all of the counties, with varying rates of positivity (Figure 4, Table 2). In
313 Mohave county there were 8/24 positive soil samples using both PCR assays (CDx and
314 CocciEnv). In Yavapai county there were 6/18 using CDx and 4/18 based on CocciENV results.
315 In Coconino county there were 6/75 positive CDx soils and none with CocciENV. Navajo county
316 had 2/32 CDx positive and none with CocciENV. Lastly, Apache county 2/22 soils which were
317 CDx positive and 3/22 CocciENV positive. In summary, 39 samples were positive for at least
318 one assay (Table 3). It is common to have varying results between the two PCR methods, both
319 which target *Coccidioides* specific alleles. Therefore, our results suggest that *Coccidioides*
320 species are present in Northern Arizona soil. If we consider samples positive for both PCR
321 methods, we identified six positive soils, which provides evidence that *C. posadasii* is present at
322 these sites.

323



324

325 Figure 4. Northern Arizona soils are positive for *Coccidioides* DNA. 4A) Percent positivity for
 326 soil in Mohave, Yavapai, Coconino, Navajo and Apache county. 4B) Approximate location of
 327 soil collection sites designated with asterisk *. Tribal land located in Northern Arizona counties
 328 are shaded.

329 Table 2. Evidence for *Coccidioides* in northern Arizona county soils.

PCR results for CDX and CocciENV assays							
County	Total samples	CDx % (n)		CocciENV % (n)		CDx and CocciENV assays	
		Positive	Negative	Positive	Negative	Positive	Negative
Mohave	32	33% (11)	66% (21)	6.25% (2)	93.75% (30)	2	21
Yavapai	18	33% (6)	66% (12)	22% (4)	78% (14)	3	11
Coconino	81	7.4% (6)	92.59% (75)	0	100% (81)	0	75
Navajo	32	6% (2)	94% (30)	0% (0)	100% (30)	0	30
Apache	22	9% (2)	91% (20)	13% (3)	87% (20)	1	18
Total	171	24	147	15	147	6	155

330

331 **Discussion**

332 Environmentally acquired diseases involve complex interactions between pathogen, host
333 and the environment. Each of these factors play a role in the outcome of infectious diseases. For
334 Valley fever, individuals become exposed to fungal propagules that originate in arid desert soils.
335 Alarming, the recognized soil habitat of *Coccidioides spp.* is actively expanding to regions as
336 far north as Washington state and predicted to continue in response to climate variability (55, 57,
337 58). In the southwestern United States where the desert environment supports fungal growth,
338 exposure is likely inevitable for long term residents. This residential population is steadily
339 increasing, often at a faster rate than the rest of the country combined, which results in an
340 increase in naïve hosts (73). Indeed, these fungal infections are on the rise in the southwestern
341 United States with most cases occurring in California and Arizona (55, 57, 58, 62). The number
342 of reported cases in Arizona have been increasing, and here we focus on the northern counties of
343 the state which are following this trend. In order to create a holistic view of coccidioidomycosis
344 in Northern Arizona, we investigated the patterns of documented susceptible hosts, population
345 structure of the local fungal isolates and the likelihood of the environment supporting the
346 pathogens existence.

347 In Arizona it is mandatory to report confirmed cases of Valley fever, which allowed us to
348 investigate current reported cases in comparison to historical trends. For each northern Arizona
349 county, the number of total cases and cases per 100,000 population has trended up each year
350 (supplemental tables 3 and 4). In Yavapai, Mohave and Apache counties, the number of cases
351 per 100,000 doubled by 2019 in comparison to historical averages from 2012-2016 (Figure 1,
352 supplemental table 3). Whether these infections are the result of travel to endemic regions of
353 southern Arizona is unknown. Although the results of our soil survey suggest the pathogen may
354 already be present in the region, travel between southern and northern Arizona is common and

355 the more likely explanation (Table 2). We anticipated that regardless of the region of infection,
356 host factors that lead to susceptibility would be similar. As suspected, individuals that test
357 positive for coccidioidomycosis in northern Arizona counties share similar sex and age
358 demographics as compared to state data (Figure 2A, supplemental table 5). Statewide, the ratio
359 of male to females with a confirmed case of Valley fever is typically 50/50 with slight variation
360 (48/52 in 2018) between each year (60). Individuals ages 45-64 are the most commonly
361 diagnosed with Valley fever in Arizona, in the northern Arizona counties similar observations
362 occurred. Because these observations are analogous in northern counties, physicians in the area
363 should consider increased screening for Valley fever, especially among individuals age 45-64
364 who display symptoms of respiratory infection.

365 In this study, we demonstrate that thirty-eight cases of Valley fever were treated at the
366 regional medical center during an 18-month period. We set out to compare these northern
367 Arizona in-patients to the greater Arizona statewide Valley fever populations to determine if any
368 other factors were contributing to disease and again found similar trends in regard to age and sex
369 (Table 1, Figure 2). Racial category is a crucial but often missing factor we identified during our
370 study. In total, 57.8% (22/38) of the patients identified as AI/AN (Table 2). Sixty percent is a
371 value higher than expected given that NAH's typical patient population is 35% AI/AN (Table 1).
372 We acknowledge that many socioeconomic factors such as access to healthy food, income level
373 and quality healthcare can play a role in disease response (74-76). Untangling the complexity of
374 racism and health disparities is a long-standing challenge in epidemiology studies (77).
375 Importantly, overwhelming evidence suggest race as it relates to disease susceptibility is a proxy
376 for a number of underlying factors and that socioeconomic status (SES) rather than racial
377 variation influences health outcomes (29, 77, 78). Nevertheless, in Arizona, over 70% of

378 documented statewide cases do not include race/ethnicity in the disease report. Therefore,
379 identifying an expected distribution of Valley fever cases across racial categories is inaccurate
380 with currently available data (Table 2) (60). The racial diversity in northern Arizona is quite
381 different than the southern parts of the state, specifically in regard to Native populations (79, 80).
382 In total American Indian/Alaskan Natives (AI/AN) make up only 4% of the Arizona population.
383 In contrast, large areas of tribal land exist in Coconino, Navajo and Apache counties hence the
384 percent of tribal members are higher than any other counties in the state (Figure 1 and 2).
385 Therefore, compared to other races and the total population in each county the percentage of
386 AI/AN individuals documented in Coconino county is 26%, in Navajo county is 44% and
387 Apache county is 73%. In contrast, tribal area is smaller in Mohave and Yavapai counties, and
388 therefore the percent of AI/AN in respect to the total populations is 2.2% and 1.6% respectively
389 (supplemental table 6). Research on the susceptibility of native populations to develop severe
390 Valley fever has always suggested concern. In 1974, it was reported that southwestern tribal
391 members had three to five times higher morbidity and mortality rates, compared to whites
392 located in or near the same region, in response to Valley fever (81). A follow up paper in 1985
393 focused on a decreased dissemination in southern tribes (from 8.9-3.9%) however, elevated
394 mortality rates of native patients compared to that of white populations in the same region still
395 remained (82). More recently, a substantial proportion of Valley fever samples collected in New
396 Mexico were derived from Native American patients (59). At a similar time, the Center for
397 Disease Control (CDC) identified that native populations suffered the highest rate of
398 coccidioidomycosis associated hospitalization out of any other race nationwide (27). The
399 discussion emphasized that increased dissemination and mortality rates of coccidioidomycosis in

400 part were due to delayed diagnosis, which further supports that access to quality healthcare or
401 other SES factors influence disease outcomes(27, 74, 77, 83).

402 Delays in diagnosis are particularly problematic in symptomatic Valley fever cases.
403 Rapid and accurate diagnosis allows clinicians to monitor disease progression, and determine the
404 appropriate intervention strategies. In contrast, severe disease or dissemination can occur when
405 symptomatic disease is left untreated (25). Our chart review suggests that many of the NAH
406 patients had co-morbidities such as HIV, cancer, or diabetes, which are known to increase
407 disease susceptibility. However, 23% of the patients did not have any immune suppression
408 conditions other than Valley fever, reminding us that this disease can be damaging to otherwise
409 healthy individuals. Of the hospitalized patients 19% had fungal infections disseminate beyond
410 the respiratory system. These data on dissemination are beyond the 1-5% estimate that is
411 expected for Valley fever (25, 32). Interestingly, six or 85% of these disseminated cases
412 identified as AI/AN. This again suggests that tribal members may be at increased risk for
413 dissemination compared to other races, as proposed previously (27, 81). Of note, the CDC report
414 did suggest that the high level of coccidioidomycosis could be due the high proportion of
415 individuals that live in the endemic region (southwestern US). Our study is focused on northern
416 Arizona which includes a large proportion of tribal land (which extends into CO, NM and UT).
417 While this area is in/near the endemic zone, it is not an area traditionally considered to be high
418 risk for acquiring the disease (Figure 1 and 2). The risk may be higher than originally thought
419 based on the increasing county Valley fever case counts per 100,000 population and
420 hospitalizations reported in northern Arizona. Previously, health disparities for AI/AN have been
421 documented for other diseases (83, 84). If NAH is treating a higher proportion of AI/AN with
422 Valley fever than expected, these findings are consistent with calculations performed by the

423 CDC and follow up studies should be designed to address this observation, while considering
424 race and SES factors (27, 78). Whether the risk is due to racism, discrimination, socioeconomic
425 variables, genetic factors, and/or the presence of environmental pathogens, it should be more
426 formally investigated. Our report indicates that a general increased awareness among hospitals,
427 physicians and local populations in Northern Arizona is needed to quickly identify and treat
428 *Coccidioides* infections.

429 Working with *Coccidioides* spp. requires biosafety level 3 (BSL-3) containment and
430 therefore culturing is not the primary method of diagnosis for most clinical laboratories, limiting
431 the availability of clinical isolates. The seven isolates obtained at NAH represent a unique
432 opportunity to investigate the pathogen component of infections in the region. The *Coccidioides*
433 genus is comprised of two genetically distinct species, each with geographically defined
434 subpopulations (38, 40). *C. immitis* found in California and Washington and *C. posadasii* found
435 in Arizona, Texas, Mexico and Latin America (38, 40-42, 54, 55). Interestingly, a recent
436 publication documented *Coccidioides* isolates from New Mexico patients represent both *C.*
437 *immitis* and *C. posadasii* infections, it is likely that *C. immitis* infections are travel related (59).
438 Because geographic origin of the fungus can be determined by genetics, we compared the NAH
439 isolates to previously published data sets (40-42). We identified that the newly obtained clinical
440 isolates from Coconino county are *C. posadasii* with genetic proximity to other Arizona isolates
441 that originate from southern AZ counties such as Maricopa and Pima. In contrast, the new
442 clinical isolates do not group with Tex/Mex/SA or Caribbean *C. posadasii* populations. While at
443 the time of sample collection the patients in our study resided in northern Arizona counties,
444 travel/previous residency information was sparse. One patient reported previously living in
445 California and another traveled to northern Mexico, but dates were not provided. These findings

446 demonstrate that these particular NAH patients were infected with isolates from the different
447 Arizona genotypes rather than a unique genetic variant in northern Arizona.

448 Northern Arizona's environment is not generally considered preferred habitat for
449 *Coccidioides*. This has been assumed based on the lower number of cases in the area, which,
450 when they are diagnosed, are attributed to travel or previous residency in highly endemic
451 southern regions of the state. Here we provide evidence of *Coccidioides posadasii* DNA in the
452 soil in all of the northern Arizona counties we tested. Interestingly, both CDx and CocciENV
453 assays target alleles that are unique to the genus (91, 96) respectively. Our results demonstrate
454 the presence of *Coccidioides* DNA in a wide range of northern Arizona locations, six of which
455 were positive using both assays, and thus we would expect that cases would be higher across the
456 region. A reasonable explanation would be the presence of a less virulent or novel species in the
457 region, which may not cause severe disease in humans but still be captured by the molecular
458 assays. Reduction in virulence due to evolutionary tradeoff adaptations relate to temperature,
459 precipitation, competition and biodiversity as observed in other species (85, 86). Alternatively,
460 wind dispersed *Coccidioides* arthroconidia from southern endemic regions may deposit conidia,
461 but these have only recently established in response to climate variability as predicted (58). This
462 could be an alternate explanation for the local clinical isolates grouping with southern Arizona
463 populations. The ability of arthroconidia to travel this distance and successfully propagate is
464 unknown and difficult to model. Models predict an expansion of suitable habitat, which includes
465 Northern Arizona, will soon be hospitable to *Coccidioides* in response to climate change. How
466 this will impact already present novel species or wind dispersed disease causing strains is
467 unknown.

468 **Summary**

469 Here in we discuss the complex interactions between the environmentally associated
470 fungal pathogen *Coccidioides*, which among susceptible human populations is causing the
471 disease coccidioidomycosis in northern Arizona. Our work suggests that the incidence of
472 diagnosed cases is rising in counties located in northern Arizona, some of which are severe
473 enough to require hospitalization. Individuals with confirmed cases demonstrated similar
474 demographics as the rest of the state in regard to sex and age. We observed that 57% of
475 hospitalized patients were of AI/AN heritage, however we are unable to determine if this
476 represents an increase risk without reliable statewide data on race/ethnicity of cases. Increased
477 reporting of patient race statewide is needed to identify disease trends specific to demographics
478 represented in the southwest. Lastly, we identified that the available clinical isolates from the
479 hospital are genetically related to Southern Arizona *C. posadasii* isolates and do not originate
480 from other populations found in Texas, Mexico or California. Our soil survey data suggests that
481 the pathogen is detectable in Northern Arizona soils, which has never previously been
482 recognized. This indicates the region supports the existence of *Coccidioides* species in the
483 environment. Collectively, our work describes the Valley fever disease triangle which considers
484 the interplay between host, pathogen and environment in Northern Arizona. Until disease
485 prevention is a feasible option, we anticipate that incidence of Valley fever will increase in the
486 area. Therefore, enhanced awareness and screening for the disease is vital to the communities of
487 Northern Arizona.

488 **Study Limitations**

489 To our knowledge this study is the first attempt to consider the interaction of host,
490 pathogen and environment which contribute to Valley fever in northern Arizona. Therefore,
491 results and discussion presented here are an estimate, with need for further data collection. Our

492 goal was to document Valley fever trends in northern Arizona with data at hand. We present
493 Valley fever cases and cases per 100,000 to account for reported cases and population
494 fluctuation. However, we acknowledge that the number of Valley fever tests administered
495 (positive and negative) can impact these numbers. We did not have access to these data, and thus
496 this is a limitation of our interpretation. Additionally, individuals with Valley fever must seek
497 medical care and be tested to be included in the reported case counts. Subsequently, our county
498 data and in-patient hospital data do not reflect asymptomatic cases, individuals without access to
499 medical care or misdiagnosis. Ideally, the retrospective chart review would encompass a longer
500 time span, however due to the current pandemic we chose to present the current data rather than
501 request further hospital resources. As previously mentioned, culturing is not the primary
502 determinate for Valley fever diagnosis, therefore we had limited access to clinical isolates. While
503 we were able to determine the genetic relationship of these isolates described above, we cannot
504 make inferences about the genetic or geographic relationship of infections where clinical isolates
505 were not collected. Lastly, the PCR methods utilized in this study detect *Coccidioides* DNA,
506 which does not confirm the presence of live infectious organisms, but rather suggests it.

507 **Acknowledgments** Appreciation to note.louis designs for map/figure creation (fig1,fig 4).

508 **Funding** B.M.B received funding for soil collection and analysis under ABRC 16-162415.
509 Sequencing funds were awarded to H.L.M by The Center for Ecosystem Science and
510 Society (Ecos) and the McAllister Program in Community, Culture and Environment at
511 Northern Arizona University. Isolates were collected under IBR No. 764034 through Northern
512 Arizona Healthcare as part of the Northern Arizona University Biobank. Funding for this
513 biobank was provided by the Flinn Foundation of Arizona seed grant #1978 to P. Keim and J.
514 Terriquez.

515 References

- 516 1. Scholthof KB. The disease triangle: pathogens, the environment and society. *Nat Rev*
517 *Microbiol.* 2007 Feb;5(2):152-6.
- 518 2. Burdon JJ, Zhan J. Climate change and disease in plant communities. *PLoS Biol.* 2020
519 Nov;18(11):e3000949.
- 520 3. Fisher MC, Henk DA, Briggs CJ, Brownstein JS, Madoff LC, McCraw SL, et al. Emerging
521 fungal threats to animal, plant and ecosystem health. *Nature.* 2012 Apr 11;484(7393):186-94.
- 522 4. CDC. Novel Coronavirus (2019-nCoV) Wuhan, China. 2019 [cited February 14, 2021];
523 Available from: [https://www.cdc.gov/coronavirus/2019-
524 ncov/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2Fnovel-
525 coronavirus-2019.html](https://www.cdc.gov/coronavirus/2019-ncov/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2Fnovel-coronavirus-2019.html)
- 526 5. Menachery VD, Yount BL, Jr., Debbink K, Agnihothram S, Gralinski LE, Plante JA, et al.
527 A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. *Nat*
528 *Med.* 2015 Dec;21(12):1508-13.
- 529 6. Rehman SU, Shafique L, Ihsan A, Liu Q. Evolutionary Trajectory for the Emergence of
530 Novel Coronavirus SARS-CoV-2. *Pathogens.* 2020 Mar 23;9(3).
- 531 7. Centers for Disease C, Prevention. Increase in reported coccidioidomycosis--United States,
532 1998-2011. *MMWR Morb Mortal Wkly Rep.* 2013 Mar 29;62(12):217-21.
- 533 8. Freedman MB AS, Benedict K, McCotter O, Derado G, Hoekstra R, et al. Preliminary
534 estimates of annual burden of coccidioidomycosis in the United States, 2010–2014. In: Group CS,
535 editor. *Coccidioidomycosis Study Group 61st Annual Meeting in collaboration with the 7th*
536 *International Coccidioidomycosis Symposium.* Palo Alto CA. Stanford CA: Coccidioidomycosis
537 Study Group; 2017. p. 32.
- 538 9. McCotter OZ, Benedict K, Engelthaler DM, Komatsu K, Lucas KD, Mohle-Boetani JC, et
539 al. Update on the Epidemiology of coccidioidomycosis in the United States. *Med Mycol.* 2019 Feb
540 1;57(Supplement_1):S30-S40.
- 541 10. Galgiani JN, Ampel NM, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Practice
542 guidelines for the treatment of coccidioidomycosis. *Clin Infect Dis.* 2000 Apr;30(4):658-61.
- 543 11. Thompson GR, 3rd. Pulmonary coccidioidomycosis. *Semin Respir Crit Care Med.* 2011
544 Dec;32(6):754-63.
- 545 12. Chiller T. Overview of Endemic Mycoses. *Vaccine Strategies for Endemic Fungal*
546 *Pathogens; 2019 2019; Rockville, Maryland; 2019.*
- 547 13. Chi GC, Benedict K, Beer KD, Jackson BR, McCotter O, Xie F, et al. Antibiotic and
548 antifungal treatment among persons with confirmed coccidioidomycosis - Southern California,
549 2011. *Med Mycol.* 2020 Apr 1;58(3):411-3.
- 550 14. Jones JM, Koski L, Khan M, Brady S, Sunenshine R, Komatsu KK. Coccidioidomycosis:
551 An underreported cause of death-Arizona, 2008-2013. *Med Mycol.* 2018 Feb 1;56(2):172-9.
- 552 15. Valdivia L, Nix D, Wright M, Lindberg E, Fagan T, Lieberman D, et al.
553 Coccidioidomycosis as a common cause of community-acquired pneumonia. *Emerging Infectious*
554 *Diseases.* 2006 Jun;12(6):958-62.
- 555 16. Kim MM, Blair JE, Carey EJ, Wu Q, Smilack JD. Coccidioidal pneumonia, Phoenix,
556 Arizona, USA, 2000-2004. *Emerg Infect Dis.* 2009 Mar;15(3):397-401.
- 557 17. Chang DC, Anderson S, Wannemuehler K, Engelthaler DM, Erhart L, Sunenshine RH, et
558 al. Testing for coccidioidomycosis among patients with community-acquired pneumonia. *Emerg*
559 *Infect Dis.* 2008 Jul;14(7):1053-9.

- 560 18. Chow NA, Griffin DW, Barker BM, Loparev VN, Litvintseva AP. Molecular detection of
561 airborne *Coccidioides* in Tucson, Arizona. *Med Mycol*. 2016 Aug 1;54(6):584-92.
- 562 19. Gade L, McCotter OZ, Bowers JR, Waddell V, Brady S, Carvajal JA, et al. The detection
563 of *Coccidioides* from ambient air in Phoenix, Arizona: Evidence of uneven distribution and
564 seasonality. *Med Mycol*. 2020 Jun 1;58(4):552-9.
- 565 20. Kirkland TN, Fierer J. *Coccidioides immitis* and *posadasii*; A review of their biology,
566 genomics, pathogenesis, and host immunity. *Virulence*; 2018. p. 1426-35.
- 567 21. Cole GT, Hurtgen BJ, Hung CY. Progress Toward a Human Vaccine Against
568 *Coccidioidomycosis*. *Curr Fungal Infect Rep*. 2012 Dec 1;6(4):235-44.
- 569 22. Castro-Lopez N, Hung CY. Immune Response to *Coccidioidomycosis* and the
570 Development of a Vaccine. *Microorganisms*. 2017 Mar 16;5(1).
- 571 23. Luo R, Greenberg A, Stone CD. Hospitalized burden and outcomes of coccidioidomycosis:
572 A nationwide analysis, 2005-2012. *Med Mycol*. 2017 Jun 1;55(4):368-74.
- 573 24. Masannat FY, Ampel NM. *Coccidioidomycosis* in patients with HIV-1 infection in the era
574 of potent antiretroviral therapy. *Clin Infect Dis*. 2010 Jan 1;50(1):1-7.
- 575 25. Odio CD, Marciano BE, Galgiani JN, Holland SM. Risk Factors for Disseminated
576 *Coccidioidomycosis*, United States. *Emerg Infect Dis*. 2017 Feb;23(2).
- 577 26. Ruddy BE, Mayer AP, Ko MG, Labonte HR, Borovansky JA, Boroff ES, et al.
578 *Coccidioidomycosis* in African Americans. *Mayo Clin Proc*. 2011 Jan;86(1):63-9.
- 579 27. McCotter O, Kennedy J, McCollum J, Bartholomew M, Iralu J, Jackson BR, et al.
580 *Coccidioidomycosis* Among American Indians and Alaska Natives, 2001-2014. *Open Forum*
581 *Infect Dis*. 2019 Mar;6(3):ofz052.
- 582 28. Galgiani JN. How does genetics influence Valley Fever? Research underway now to
583 answer this question. *AZ Medicine*. 2014;Fall:30-3.
- 584 29. El-Sayed AM. Complex systems for a complex issue: race in health research. *Virtual*
585 *Mentor*. 2014 Jun 1;16(6):450-4.
- 586 30. Lewis ER, David VR, Doyle AL, Rajabi K, Kiefer JA, Pirrotte P, et al. Differences in Host
587 Innate Responses among *Coccidioides* Isolates in a Murine Model of Pulmonary
588 *Coccidioidomycosis*. *Eukaryot Cell*. 2015 Oct;14(10):1043-53.
- 589 31. Louie L, Ng S, Hajjeh R, Johnson R, Vugia D, Werner SB, et al. Influence of host genetics
590 on the severity of coccidioidomycosis. *Emerg Infect Dis*. 1999 Sep-Oct;5(5):672-80.
- 591 32. Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, et al. Recent
592 advances in our understanding of the environmental, epidemiological, immunological, and clinical
593 dimensions of coccidioidomycosis. *Clin Microbiol Rev*. 2013 Jul;26(3):505-25.
- 594 33. Van Dyke MCC, Teixeira MM, Barker BM. Fantastic yeasts and where to find them: the
595 hidden diversity of dimorphic fungal pathogens. *Curr Opin Microbiol*. 2019 Jun 7;52:55-63.
- 596 34. Drutz DJ, Huppert M. *Coccidioidomycosis*: factors affecting the host-parasite interaction.
597 *J Infect Dis*. 1983 Mar;147(3):372-90.
- 598 35. Cole G.T. SSH. *Arthroconidium-Spherule-Endospore Transformation in Coccidioides*
599 *immitis*. In: Szaniszló P.J., Harris J.L. (eds) *Fungal Dimorphism*. Springer, Boston, MA.; 1985. p.
600 281-333.
- 601 36. Sil A, Andrianopoulos A. Thermally Dimorphic Human Fungal Pathogens--Polyphyletic
602 Pathogens with a Convergent Pathogenicity Trait. *Cold Spring Harb Perspect Med*. 2014 Nov
603 10;5(8):a019794.

- 604 37. Sharpton TJ, Stajich JE, Rounsley SD, Gardner MJ, Wortman JR, Jordar VS, et al.
605 Comparative genomic analyses of the human fungal pathogens *Coccidioides* and their relatives.
606 *Genome Res.* 2009 Oct;19(10):1722-31.
- 607 38. Fisher MC, Koenig GL, White TJ, Taylor JW. Molecular and phenotypic description of
608 *Coccidioides posadasii* sp. nov., previously recognized as the non-California population of
609 *Coccidioides immitis*. *Mycologia.* 2002 Jan-Feb;94(1):73-84.
- 610 39. Barker BM, Tabor JA, Shubitz LF, Perrill R, Orbach MJ. Detection and phylogenetic
611 analysis of *Coccidioides posadasii* in Arizona soil samples. *Fungal Ecol.* 2012;5(2):163-76.
- 612 40. Engelthaler DM, Roe CC, Hepp CM, Teixeira M, Driebe EM, Schupp JM, et al. Local
613 Population Structure and Patterns of Western Hemisphere Dispersal for *Coccidioides* spp., the
614 Fungal Cause of Valley Fever. *MBio.* 2016 Apr 26;7(2):e00550-16.
- 615 41. Teixeira MM, Alvarado P, Roe CC, Thompson GR, 3rd, Patane JSL, Sahl JW, et al.
616 Population Structure and Genetic Diversity among Isolates of *Coccidioides posadasii* in Venezuela
617 and Surrounding Regions. *mBio.* 2019 Nov 26;10(6).
- 618 42. Teixeira MM, Barker BM. Use of Population Genetics to Assess the Ecology, Evolution,
619 and Population Structure of *Coccidioides*. *Emerg Infect Dis.* 2016 Jun;22(6):1022-30.
- 620 43. Berman RJ, Friedman L, Roessler WG, Smith CE. The virulence and infectivity of twenty-
621 seven strains of *Coccidioides immitis*. *Am J Hyg.* 1956 Sep;64(2):198-210.
- 622 44. Friedman L, Smith CE, Gordon LE. The assay of virulence of *Coccidioides* in white mice.
623 *J Infec Dis.* 1955 Nov-Dec;97(3):311-6.
- 624 45. Cox RA, Magee DM. Coccidioidomycosis: host response and vaccine development. *Clin*
625 *Microbiol Rev.* 2004 Oct;17(4):804-39, table of contents.
- 626 46. Shubitz LF, Powell DA, Butkiewicz CD, Lewis ML, Trinh HT, Frelinger JA, et al. A
627 Chronic Murine Disease Model of Coccidioidomycosis Using *Coccidioides posadasii*, strain 1038.
628 2020 in press.
- 629 47. Shubitz LF PD, Butkiewicz CD, Lewis ML, Trinh HT, Frelinger JA, Orbach MJ, Galgiani
630 JN,. A Chronic Murine Disease Model of Coccidioidomycosis Using *Coccidioides posadasii*,
631 strain 1038. *Journal Infectious Disease*; 2020.
- 632 48. Taylor JW, Barker BM. The endozoan, small-mammal reservoir hypothesis and the life
633 cycle of *Coccidioides* species. *Med Mycol.* 2019 Feb 1;57(Supplement_1):S16-S20.
- 634 49. Kollath DR, Teixeira MM, Funke A, Miller KJ, Barker BM. Investigating the Role of
635 Animal Burrows on the Ecology and Distribution of *Coccidioides* spp. in Arizona Soils.
636 *Mycopathologia.* 2020 Feb;185(1):145-59.
- 637 50. Alvarado P, Teixeira MM, Andrews L, Fernandez A, Santander G, Doyle A, et al.
638 Detection of *Coccidioides posadasii* from xerophytic environments in Venezuela reveals risk of
639 naturally acquired coccidioidomycosis infections. *Emerg Microbes Infect.* 2018 Mar 29;7(1):46.
- 640 51. Baptista-Rosas RC C-DJ, Romero-Olivares AL, Hinojosa A, Cavazos T, Riquelme M.
641 Molecular detection of *Coccidioides* spp. from environmental samples in Baja California: linking
642 Valley Fever to soil and climate conditions. *Fungal Ecol.*; 2012. p. 177–90.
- 643 52. Johnson SM, Carlson EL, Fisher FS, Pappagianis D. Demonstration of *Coccidioides*
644 *immitis* and *Coccidioides posadasii* DNA in soil samples collected from Dinosaur National
645 Monument, Utah. *Med Mycol.* 2014 Aug;52(6):610-7.
- 646 53. Eulalio KD, de Macedo RL, Cavalcanti MA, Martins LM, Lazera MS, Wanke B.
647 *Coccidioides immitis* isolated from armadillos (*Dasypus novemcinctus*) in the state of Piauí,
648 northeast Brazil. *Mycopathologia.* 2001;149(2):57-61.

- 649 54. Fisher MC, Koenig GL, White TJ, San-Blas G, Negroni R, Alvarez IG, et al. Biogeographic
650 range expansion into South America by *Coccidioides immitis* mirrors New World patterns of
651 human migration. *Proc Natl Acad Sci U S A*. 2001 Apr 10;98(8):4558-62.
- 652 55. Litvintseva AP, Marsden-Haug N, Hurst S, Hill H, Gade L, Driebe EM, et al. Valley fever:
653 finding new places for an old disease: *Coccidioides immitis* found in Washington State soil
654 associated with recent human infection. *Clinical infectious diseases : an official publication of the*
655 *Infectious Diseases Society of America*. 2015 Jan 1;60(1):e1-3.
- 656 56. Marsden-Haug N, Goldoft M, Ralston C, Limaye AP, Chua J, Hill H, et al.
657 *Coccidioidomycosis* acquired in Washington State. *Clin Infect Dis*. 2013 Mar;56(6):847-50.
- 658 57. Gorris ME, Cat LA, Zender CS, Treseder KK, Randerson JT. *Coccidioidomycosis*
659 *Dynamics in Relation to Climate in the Southwestern United States*. *Geohealth*. 2018 Jan;2(1):6-
660 24.
- 661 58. Gorris ME, Treseder KK, Zender CS, Randerson JT. Expansion of *Coccidioidomycosis*
662 *Endemic Regions in the United States in Response to Climate Change*. *Geohealth*. 2019
663 Oct;3(10):308-27.
- 664 59. Hamm PS, Hutchison MI, Leonard P, Melman S, Natvig DO. First Analysis of Human
665 *Coccidioides* Isolates from New Mexico and the Southwest Four Corners Region: Implications for
666 the Distributions of *C. posadasii* and *C. immitis* and Human Groups at Risk. *Journal of fungi*
667 (Basel). 2019 Aug 10;5(3).
- 668 60. AZDHS. Valley Fever Data, Reports & Publications. [cited; Available from:
669 [https://www.azdhs.gov/preparedness/epidemiology-disease-control/valley-](https://www.azdhs.gov/preparedness/epidemiology-disease-control/valley-fever/index.php#reports-publications)
670 [fever/index.php#reports-publications](https://www.azdhs.gov/preparedness/epidemiology-disease-control/valley-fever/index.php#reports-publications)
- 671 61. !!! INVALID CITATION !!! (8).
- 672 62. Bezold CP, Khan MA, Adame G, Brady S, Sunenshine R, Komatsu K. Notes from the
673 Field: Increase in *Coccidioidomycosis* - Arizona, October 2017-March 2018. *MMWR Morb*
674 *Mortal Wkly Rep*. 2018 Nov 9;67(44):1246-7.
- 675 63. Services ADoH. Valley fever Data, Reports & Publications
676 . online: Arizona Department of Health Services.
- 677 64. Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition.
- 678 65. Mead HL, Blackmon VA, Vogler JA, Barker MB. Heat Inactivation of *Coccidioides*
679 *posadasii* and *Coccidioides immitis* for Use in Lower Biosafety Containment. *Applied Biosafety*.
680 2019 2019-06-16.
- 681 66. Mead HL, Van Dyke MCC, Barker BM. Proper Care and Feeding of *Coccidioides*: A
682 *Laboratorian's Guide to Cultivating the Dimorphic Stages of C. immitis* and *C. posadasii*. *Curr*
683 *Protoc Microbiol*. 2020 Sep;58(1):e113.
- 684 67. Sahl JW, Lemmer D, Travis J, Schupp JM, Gillece JD, Aziz M, et al. NASP: an accurate,
685 rapid method for the identification of SNPs in WGS datasets that supports flexible input and output
686 formats. *Microb Genom*. 2016 Aug;2(8):e000074.
- 687 68. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective
688 stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol*. 2015
689 Jan;32(1):268-74.
- 690 69. Rambaut A. FigTree v1.4.4. p. FigTree is designed as a graphical viewer of phylogenetic
691 trees and as a program for producing publication-ready figures.
- 692 70. Bowers JR, Parise KL, Kelley EJ, Lemmer D, Schupp JM, Driebe EM, et al. Direct
693 detection of *Coccidioides* from Arizona soils using CocciENV, a highly sensitive and specific real-
694 time PCR assay. *Med Mycol*. 2019 Feb;57(2):246-55.

- 695 71. Saubolle MA, Wojack BR, Wertheimer AM, Fuayagem AZ, Young S, Koeneman BA.
696 Multicenter Clinical Validation of a Cartridge-Based Real-Time PCR System for Detection of
697 *Coccidioides* spp. in Lower Respiratory Specimens. *J Clin Microbiol*. 2018 Feb;56(2).
- 698 72. Brown J, Benedict K, Park BJ, Thompson GR, 3rd. *Coccidioidomycosis: epidemiology.*
699 *Clin Epidemiol*. 2013;5:185-97.
- 700 73. Bureau USC. The Desert Southwest.
- 701 74. Charles MA. Developmental origins of adult health and disease: an important concept for
702 social inequalities in health. *Rev Epidemiol Sante Publique*. 2013 Aug;61 Suppl 3:S133-8.
- 703 75. Cunningham AA, Scoones I, Wood JLN. One Health for a changing world: new
704 perspectives from Africa. *Philos Trans R Soc Lond B Biol Sci*. 2017 Jul 19;372(1725).
- 705 76. Marmot M. Economic and social determinants of disease. *Bull World Health Organ*.
706 2001;79(10):988-9.
- 707 77. Egede LE. Race, ethnicity, culture, and disparities in health care. *J Gen Intern Med*. 2006
708 Jun;21(6):667-9.
- 709 78. Collins FS. What we do and don't know about 'race', 'ethnicity', genetics and health at the
710 dawn of the genome era. *Nat Genet*. 2004 Nov;36(11 Suppl):S13-5.
- 711 79. Museum AS. Federally Recognized Tribes in Arizona. 2021 [cited 2/20/21]; Available
712 from: <https://statemuseum.arizona.edu/programs/american-indian-relations/tribes-arizona>
- 713 80. Health ADo. Population Health and Vital Statistics. 2021 [cited 02/20/2021]; Available
714 from: <https://pub.azdhs.gov/health-stats/menu/info/pop/index.php>
- 715 81. Sievers ML. Disseminated *Coccidioidomycosis* among Southwestern American Indians.
716 *Am Rev Respir Dis*. 1974;109(6):602-12.
- 717 82. Sievers ML, Fisher JR. Decreasing Incidence of Disseminated *Coccidioidomycosis* among
718 Piman and San-Carlos Apache Indians - a Probable Environmental Basis. *Chest*. 1982;82(4):455-
719 60.
- 720 83. Holman RC, Folkema AM, Singleton RJ, Redd JT, Christensen KY, Steiner CA, et al.
721 Disparities in Infectious Disease Hospitalizations for American Indian/Alaska Native People.
722 *Public Health Reports*. 2011 Jul-Aug;126(4):508-21.
- 723 84. Cheek JE, Holman RC, Redd JT, Haberling D, Hennessy TW. Infectious Disease Mortality
724 Among American Indians and Alaska Natives, 1999-2009. *American Journal of Public Health*.
725 2014 Jun;104:S446-S52.
- 726 85. Barton IS, Fuqua C, Platt TG. Ecological and evolutionary dynamics of a model facultative
727 pathogen: *Agrobacterium* and crown gall disease of plants. *Environ Microbiol*. 2018 Jan;20(1):16-
728 29.
- 729 86. Suzuki SU, Sasaki A. Ecological and Evolutionary Stabilities of Biotrophism,
730 Necrotrophism, and Saprotrophism. *Am Nat*. 2019 Jul;194(1):90-103.
- 731